Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study.
作者信息
Guss Debra A, Mohanty Smruti R
机构信息
Division of Gastroenterology & Hepatobiliary Disease, Center for Liver Diseases, New York Methodist Hospital, Brooklyn, NY, USA.
出版信息
Hepatobiliary Surg Nutr. 2016 Dec;5(6):515-518. doi: 10.21037/hbsn.2016.11.09.
Abstract
摘要
相似文献
1
Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study.利拉鲁肽在非酒精性脂肪性肝病治疗中的应用：非酒精性脂肪性肝炎研究评估
Hepatobiliary Surg Nutr. 2016 Dec;5(6):515-518. doi: 10.21037/hbsn.2016.11.09.
2
Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.非酒精性脂肪性肝炎患者血浆转化生长因子-β1水平及α-生育酚的疗效：一项初步研究
Aliment Pharmacol Ther. 2001 Oct;15(10):1667-72. doi: 10.1046/j.1365-2036.2001.01083.x.
3
A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患儿非酒精性脂肪性肝炎的无创预测模型
Dig Liver Dis. 2014 Nov;46(11):1008-13. doi: 10.1016/j.dld.2014.07.016. Epub 2014 Aug 6.
4
CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.CD36 的棕榈酰化作用破坏游离脂肪酸代谢并促进非酒精性脂肪性肝炎中的组织炎症。
J Hepatol. 2018 Sep;69(3):705-717. doi: 10.1016/j.jhep.2018.04.006. Epub 2018 Apr 27.
5
Evaluation and management of non-alcoholic steatohepatitis.
Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1117-22. doi: 10.1097/00042737-200411000-00005.
6
Unique microbial-derived volatile organic compounds in portal venous circulation in murine non-alcoholic fatty liver disease.小鼠非酒精性脂肪性肝病门静脉循环中独特的微生物衍生挥发性有机化合物
Biochim Biophys Acta. 2016 Jul;1862(7):1337-44. doi: 10.1016/j.bbadis.2016.04.005. Epub 2016 Apr 13.
7
Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者血浆同型半胱氨酸浓度升高作为脂肪性肝炎的预测指标
J Gastroenterol Hepatol. 2005 Sep;20(9):1448-55. doi: 10.1111/j.1440-1746.2005.03891.x.
8
A Case of Concomitant Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis Treated With CPAP Therapy.1例阻塞性睡眠呼吸暂停合并非酒精性脂肪性肝炎患者接受持续气道正压通气（CPAP）治疗的病例
Gastroenterology Res. 2018 Jun;11(3):252-259. doi: 10.14740/gr1033w. Epub 2018 May 31.
9
Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.活检证实的非酒精性脂肪性肝炎（NASH）肥胖小鼠模型中基于活检的药物疗效的有效性。
BMC Gastroenterol. 2019 Dec 28;19(1):228. doi: 10.1186/s12876-019-1149-z.
10
Metabolic factors affecting hepatocellular carcinoma in steatohepatitis.影响脂肪性肝炎中肝细胞癌的代谢因素。
Liver Int. 2019 Mar;39(3):531-539. doi: 10.1111/liv.14002. Epub 2018 Dec 2.
引用本文的文献
1
MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk.MAFLD：代谢功能障碍与心血管风险之间联系的全面综述
Hepat Med. 2025 Aug 19;17:75-90. doi: 10.2147/HMER.S506402. eCollection 2025.
2
A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).2 型糖尿病伴非酒精性脂肪性肝病的胰高血糖素样肽 1 受体激动剂（GLP1-RA）作用的荟萃分析。
Sci Rep. 2021 Nov 11;11(1):22063. doi: 10.1038/s41598-021-01663-y.
本文引用的文献
1
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.利拉鲁肽治疗非酒精性脂肪性肝炎（LEAN）患者的安全性和有效性：一项多中心、双盲、随机、安慰剂对照的 2 期研究。
Lancet. 2016 Feb 13;387(10019):679-690. doi: 10.1016/S0140-6736(15)00803-X. Epub 2015 Nov 20.
2
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.药物干预非酒精性脂肪性肝炎的疗效比较：系统评价和网络荟萃分析。
Hepatology. 2015 Nov;62(5):1417-32. doi: 10.1002/hep.27999. Epub 2015 Oct 1.
3
Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.非酒精性脂肪性肝炎是美国等待肝移植的成年人中导致肝病的第二大病因。
Gastroenterology. 2015 Mar;148(3):547-55. doi: 10.1053/j.gastro.2014.11.039. Epub 2014 Nov 25.
4
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会、美国胃肠病学会和美国胃肠病协会实践指南
Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.
5
Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts.诊断非酒精性脂肪性肝病患者的脂肪性肝炎并预测肝脏相关死亡率：两个不同的概念。
Hepatology. 2011 Jun;53(6):1792-4. doi: 10.1002/hep.24403.
6
Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role?在弗雷明汉心脏研究中维生素E补充剂的使用与心血管疾病发病率及全因死亡率：潜在健康状况起作用吗？
Atherosclerosis. 2009 Aug;205(2):549-53. doi: 10.1016/j.atherosclerosis.2008.12.019. Epub 2008 Dec 24.
Zotero 插件